Background: In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), selecting an antithrombotic regimen requires balancing risks of ischemic cardiac events, stroke, and bleeding.
Methods: We studied 467 patients with AF undergoing PCI in the time period from December 2015 to July 2018 identified via a chart audit by 47 Canadian cardiologists in the CONNECT AF+PCI (the ordinated ational etwork to ngage Interventional ardiologists in the Antithrombotic reatment of Patients With trial ibrillation Undergoing ercutaneous oronary ntervention) study, to determine patterns of initial antithrombotic therapy selection.
Results: The median (25th, 75th percentile) CHADS score was 2 (1, 3), and PCI was performed in the setting of acute coronary syndrome in 62.1%. Triple antithrombotic therapy (TAT) was the initial treatment in 62.7%, dual-pathway therapy in 25.7%, and dual antiplatelet therapy in 11.6%, with a temporal increase in use of dual-pathway therapy during the course of the study; median intended TAT duration was 1 (1, 3) month. Compared with patients selected for TAT, patients selected for dual-pathway therapy were less likely to have prior myocardial infarction (35.8% vs 25.8%, = 0.045) and prior PCI (33.8% vs 23.3%, = 0.03), and they received shorter total length of stents (38 [23, 56] vs 30 [20, 46] mm, = 0.03). Patients selected for dual-pathway therapy had a higher prevalence of prior stroke/transient ischemic attack (13.0% vs 23.3%, = 0.01). There was no difference in prevalence of anemia (21.5% vs 25.8%, = 0.30). Use of dual-pathway therapy was similar among patients with acute coronary syndrome and those with stable disease (24.1% vs 28.2%, = 0.32).
Conclusions: Approximately one-quarter of AF patients undergoing PCI are treated with dual-pathway therapy in Canadian practice, with its use increasing during the studied period. Patients selected for dual-pathway therapy have less-complex coronary disease history and intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712598 | PMC |
| http://dx.doi.org/10.1016/j.cjco.2021.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Peripheral arterial disease: 2024 update].
Rev Med Suisse
November 2024
Département de médecine et centre vasculaire, Réseau hospitalier neuchâtelois, 2000 Neuchâtel.
Peripheral arterial disease (PAD) is a major public health issue, with a growing prevalence due to the aging population and the rise in risk factors such as diabetes, hypertension, and dyslipidemia. Managing PAD involves a multidisciplinary approach, with the primary care physician playing a crucial role in early screening. This article compiles the latest data from 2024 and current practices for the management of this disease.
View Article and Find Full Text PDFRivaroxaban plus aspirin after lower-extremity revascularization.
Expert Rev Hematol
December 2024
Population Health Research Institute, Hamilton, ON, Canada.
Introduction: Patients undergoing revascularization of the lower extremities have unacceptably high rates of major adverse cardiac and limb events despite the routine use of antiplatelet therapy. Optimization of antithrombotic therapy provides an opportunity to reduce this risk. Recent large, randomized trials have demonstrated substantial benefit from the combination of low-dose rivaroxaban and aspirin compared with aspirin alone.
View Article and Find Full Text PDF[Dual pathway inhibition in peripheral arterial disease].
G Ital Cardiol (Rome)
November 2024
U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
Despite its high worldwide prevalence and the intuitable negative prognostic connotation, for a long time peripheral artery disease (PAD) has not been the subject of particular interest by the cardiac scientific community. The availability of a new therapeutic strategy (low-dose rivaroxaban associated with acetylsalicylic acid) has reignited interest in PAD. The clear evidence derived from the COMPASS and VOYAGER PAD trials, with the possibility of using dual pathway inhibition, has given new energy to the therapeutic front against symptomatic PAD also associated with coronary artery disease.
View Article and Find Full Text PDFDual-responsive nanoplatform for integrated cancer diagnosis and therapy: Unleashing the power of tumor microenvironment.
Front Chem
September 2024
Department of Radiology, The Second Hospital of Jilin University, Changchun, China.
Article Synopsis
- * To improve CDT, researchers have created a dual-responsive nanoplatform that releases iron and enhances the therapy's effectiveness by degrading in the acidic tumor microenvironment and consuming excess GSH.
- * This new nanoplatform also supports photothermal therapy (PTT) and has advanced imaging capabilities for early diagnosis, showcasing its potential as a multifunctional tool in cancer treatment.
Postoperative Injection of a Triptolide-Preloaded Hydrogel Prevents the Recurrence of Glioblastoma by Dual-Pathway Activation of Ferroptosis.
Small
December 2024
Department of Cell Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211166, P. R. China.
Article Synopsis
- A new injectable hydrogel, TP@DNH, is developed to help prevent the recurrence of glioblastoma (GBM) after surgery by using triptolide to trigger a form of cell death called ferroptosis.
- This hydrogel targets a specific cellular pathway that involves deactivating GPX4, which is crucial for neutralizing harmful substances in GBM cells, leading to increased levels of reactive oxygen species (ROS).
- In tests with mice, the TP@DNH hydrogel significantly slows down the growth of recurrent GBM and improves overall survival, suggesting a promising new approach for postoperative GBM treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!